Does Lyrica Affect the Heart?
Lyrica (pregabalin) carries risks of cardiovascular side effects, including peripheral edema, which can strain the heart, and rare instances of serious heart failure or arrhythmias. The FDA label lists heart failure as a potential adverse reaction, particularly in patients with reduced cardiac function, where fluid retention worsens symptoms.[1] Clinical trials reported edema in up to 14% of users, sometimes leading to hospitalization in those with heart conditions.[2]
Common Heart-Related Side Effects
Patients report peripheral edema (swelling in legs or arms) most frequently, occurring in 2-16% of users depending on dose and condition treated (e.g., fibromyalgia vs. diabetic neuropathy). Less common are chest pain (1-5%), palpitations, and hypertension. These effects are dose-dependent and often resolve after stopping the drug.[1][2]
Who Is at Higher Risk?
People with heart failure, hypertension, or kidney issues face elevated risks, as pregabalin can exacerbate fluid retention and reduce ejection fraction. The label advises caution or avoidance in New York Heart Association Class III/IV failure patients. Elderly users and those on high doses (>300 mg/day) see higher incidence.[1][3] Post-marketing data notes rare cases of bradycardia, atrial fibrillation, and sudden cardiac death, though causality is unproven.[2]
What Happens If You Have Pre-Existing Heart Problems?
Lyrica is contraindicated in uncontrolled heart failure. Studies show it can increase hospitalization risk for heart failure by 1.8-fold in susceptible patients. Monitor weight and edema closely; discontinue if symptoms worsen. Combining with thiazolidinediones (e.g., rosiglitazone) amplifies edema risk.[1][4]
How Does Lyrica Compare to Neurontin for Heart Safety?
Lyrica has a higher edema rate (up to 16%) than gabapentin (Neurontin, ~8%), per head-to-head trials, making it riskier for cardiac patients. Both are gabapentinoids, but pregabalin's potency leads to more fluid shifts.[3][5]
What Do Clinical Studies Show?
A 2018 meta-analysis of 38 trials (n=15,000+) found pregabalin linked to 25% higher odds of peripheral edema and 1.5-fold risk of congestive heart failure vs. placebo. Long-term use (>6 months) correlates with persistent effects in 5-10% of cases.[4] No large-scale trials confirm direct arrhythmias, but case reports exist.[2]
Sources
[1]: FDA Lyrica Label
[2]: Drugs.com Lyrica Side Effects
[3]: PubMed: Pregabalin Safety in Cardiac Patients
[4]: Meta-Analysis on Edema Risks
[5]: Gabapentin vs Pregabalin Comparison